Peptide microarray analysis of in silico-predicted epitopes for serological diagnosis of Toxoplasma gondii infection in humans

Clinical and Vaccine Immunology

Volumn 19, Issue 6, 2012, Pages 865-874

  Maksimov, Pavlo ^a   Zerweck, Johannes ^b   Maksimov, Aline ^a   Hotop, Andrea ^c   Groß, Uwe ^c   Pleyer, Uwe ^d   Spekker, Katrin ^e   Däubener, Walter ^e   Werdermann, Sandra ^f   Niederstrasser, Olaf ^g   Petri, Eckhardt ^h   Mertens, Marc ^a   Ulrich, Rainer G ^a   Conraths, Franz J ^a   Schares, Gereon ^a  

^a FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^b JPT Peptide Technologies GmbH   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f Institut für Arbeits und Sozialhygiene Stiftung   (Germany)

^g Helios Kliniken   (Germany)

^h GSK Marburg Vaccines and Diagnostics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GRA1 PROTEIN; GRA2 PROTEIN; GRA4 PROTEIN; MIC3 PROTEIN; NTPASE 1; NTPASE 2; PROTOZOAL PROTEIN; SAG1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; BLOOD SAMPLING; COMPUTER PREDICTION; COMPUTER PROGRAM; CONTROLLED STUDY; DIAGNOSTIC VALUE; FOREST WORKER; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN MICROARRAY; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TOXOPLASMOSIS;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; COMPUTATIONAL BIOLOGY; EPITOPES; HUMANS; IMMUNOASSAY; PROTEIN ARRAY ANALYSIS; PROTOZOAN PROTEINS; SENSITIVITY AND SPECIFICITY; TOXOPLASMA; TOXOPLASMOSIS;

EID: 84861740669     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00119-12     Document Type: Article

References (58)

1. Alcaro MC, Peroni E, Rovero P, Papini AM. 2003. Synthetic peptides in the diagnosis of HIV infection. Curr. Protein Pept. Sci. 4:285-290. (Pubitemid 36975110)
2. Altcheh J, et al. 2006. Kinetic analysis of the humoral immune response against 3 Toxoplasma gondii-recombinant proteins in infants with suspected congenital toxoplasmosis. Diagn. Microbiol. Infect. Dis. 56:161-165. (Pubitemid 44515069)
3. Bacarese-Hamilton T, Mezzasoma L, Ardizzoni A, Bistoni F, Crisanti A. 2004. Serodiagnosis of infectious diseases with antigen microarrays. J. Appl. Microbiol. 96:10-17. (Pubitemid 38177900)
4. Barlow DJ, Edwards MS, Thornton JM. 1986. Continuous and discontinuous protein antigenic determinants. Nature 322:747-748. (Pubitemid 16074126)
5. Beghetto E, et al. 2003. Use of an immunoglobulin G avidity assay based on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy. J. Clin. Microbiol. 41:5414-5418. (Pubitemid 37543225)
6. Beghetto E, et al. 2001. Identification of a human immunodominant B-cell epitope within the GRA1 antigen of Toxoplasma gondii by phage display of cDNA libraries. Int. J. Parasitol. 31:1659-1668. (Pubitemid 33152821)
7. Beghetto E, et al. 2003. Molecular dissection of the human B-cell response against Toxoplasma gondii infection by lambda display of cDNA libraries. Int. J. Parasitol. 33:163-173. (Pubitemid 36298987)
8. Blythe MJ, Flower DR. 2005. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci. 14:246-248. (Pubitemid 40054138)
9. Burg JL, Perelman D, Kasper LH, Ware PL, Boothroyd JC. 1988. Molecular analysis of the gene encoding the major surface antigen of Toxoplasma gondii. J. Immunol. 141:3584-3591.
10. Cabral HJ. 2008. Multiple comparisons procedures. Circulation 117:698-701.
11. Cardona N, de la Torre A, Siachoque H, Patarroyo MA, Gomez-Marin JE. 2009. Toxoplasma gondii: P30 peptides recognition pattern in human toxoplasmosis. Exp. Parasitol. 123:199-202.
12. Chaves-Borges FA, Souza MA, Silva DA, Kasper LH, Mineo JR. 1999. Detection of Toxoplasma gondii soluble antigen, SAG-1(p30), antibody and immune complex in the cerebrospinal fluid of HIV positive or negative individuals. Rev. Inst. Med. Trop. Sao Paulo 41:329-338.
13. Domínguez-Almendros S, Benítez-Parejo N, Gonzalez-Ramirez AR. 2011. Logistic regression models. Allergol. Immunopathol. (Madr.) 39:295-305.
14. El-Manzalawy Y, Honavar V. 2010. Recent advances in B-cell epitope prediction methods. Immunome Res. 6(Suppl. 2):S2. doi:10.1186/1745-7580-6-S2-S2.
15. Garweg JG, et al. 2005. Congenital ocular toxoplasmosis-observations on the outcome after an early diagnosis. Klin. Monbl. Augenheilkd. 222:721-727. (Pubitemid 41413723)
16. Golkar M, et al. 2007. The dense granule protein GRA2, a new marker for the serodiagnosis of acute Toxoplasma infection: comparison of sera collected in both France and Iran from pregnant women. Diagn. Microbiol. Infect. Dis. 58:419-426. (Pubitemid 47198403)
17. Groß U. 2004. Prevalence and public-health-aspects of toxoplasmosis. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:692-697. (In German.)
18. Gross U, Roos T, Appoldt D, Heesemann J. 1992. Improved serological diagnosis of Toxoplasma gondii infection by detection of immunoglobulin A (IgA) and IgM antibodies against P30 by using the immunoblot technique. J. Clin. Microbiol. 30:1436-1441.
19. Harning D, Spenter J, Metsis A, Vuust J, Petersen E. 1996. Recombinant Toxoplasma gondii surface antigen 1 (P30) expressed in Escherichia coli is recognized by human Toxoplasma-specific immunoglobulinM(IgM) and IgG antibodies. Clin. Diagn. Lab. Immunol. 3:355-357. (Pubitemid 26189640)
20. Hosseininejad M, Azizi HR, Hosseini F, Schares G. 2009. Development of an indirect ELISA test using a purified tachyzoite surface antigen SAG1 for sero-diagnosis of canine Toxoplasma gondii infection. Vet. Parasitol. 164:315-319.
21. Ismael AB, Sekkai D, Collin C, Bout D, Mévélec MN. 2003. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infect. Immun. 71:6222-6228. (Pubitemid 37337678)
22. Jamieson SE, et al. 2009. Host genetic and epigenetic factors in toxoplasmosis. Mem. Inst. Oswaldo Cruz 104:162-169.
23. Jamieson SE, et al. 2008. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One 3:e2285. doi:10.1371/journal.pone.0002285.
24. Jiang T, et al. 2008. Evaluation of a recombinant MIC3 based latex agglutination test for the rapid serodiagnosis of Toxoplasma gondii infection in swines. Vet. Parasitol. 158:51-56.
25. Johnson MS, Broady KW, Johnson AM. 1999. Differential recognition of Toxoplasma gondii recombinant nucleoside triphosphate hydrolase isoforms by naturally infected human sera. Int. J. Parasitol. 29:1893-1905.
26. Kato M, et al. 2007. Reactivity of synthetic SAG1 (p30) peptide sequences with RH, S273 and Beverley strain-induced anti-Toxoplasma gondii antibodies. Pathobiology 74:50-56. (Pubitemid 46742317)
27. Kato M, et al. 2005. Toxoplasma gondii antigens GRA1 (p24) and SAG1 (p30): a comparison of their stimulatory influence on T-cell activation and cytokine expression in in vitro cultures. Pathobiology 72:160-164. (Pubitemid 40675000)
28. Kim K, Bülow R, Kampmeier J, Boothroyd JC. 1994. Conformationally appropriate expression of the Toxoplasma antigen SAG1 (p30) in CHO cells. Infect. Immun. 62:203-209. (Pubitemid 24011960)
29. Klaren VN, Peek R. 2001. Evidence for a compartmentalized B cell response as characterized by IgG epitope specificity in human ocular toxoplasmosis. J. Immunol. 167:6263-6269. (Pubitemid 33081556)
30. Kodjikian L, et al. 2006. Ocular manifestations in congenital toxoplasmosis. Graefes Arch. Clin. Exp. Ophthalmol. 244:14-21. (Pubitemid 43013177)
31. Kong JT, Grigg ME, Uyetake L, Parmley S, Boothroyd JC. 2003. Serotyping of Toxoplasma gondii infections in humans using synthetic peptides. J. Infect. Dis. 187:1484-1495. (Pubitemid 36549695)
32. Kotresha D, Noordin R. 2010. Recombinant proteins in the diagnosis of toxoplasmosis. APMIS 118:529-542.
33. Lekutis C, Ferguson DJ, Grigg ME, Camps M, Boothroyd JC. 2001. Surface antigens of Toxoplasma gondii: variations on a theme. Int. J. Parasitol. 31:1285-1292. (Pubitemid 32868708)
34. Li S, et al. 2000. Serodiagnosis of recently acquired Toxoplasma gondii infection with a recombinant antigen. J. Clin. Microbiol. 38:179-184. (Pubitemid 30043285)
35. Liang L, et al. 2011. Identification of potential serodiagnostic and subunit vaccine antigens by antibody profiling of toxoplasmosis cases in Turkey. Mol. Cell. Proteomics 10:M110.006916. doi:10.1074/mcp.M110.006916.
36. List C, et al. 2010. Serodiagnosis of Echinococcus spp. infection: explorative selection of diagnostic antigens by peptide microarray. PLoS Negl. Trop. Dis. 4:e771. doi:10.1371/journal.pntd.0000771.
37. Lüder CG, Seeber F. 2001. Toxoplasma gondii and MHC-restricted antigen presentation: on degradation, transport and modulation. Int. J. Parasitol. 31:1355-1369. (Pubitemid 32868715)
38. Maksimov P, et al. 2011. Serological survey and risk factors for Toxoplasma gondii in domestic ducks and geese in Lower Saxony, Germany. Vet. Parasitol. 182:140-149.
39. Maksimov P, et al. 2012. Analysis of clonal type-specific antibody reactions in Toxoplasma gondii seropositive humans from Germany by peptide-microarray. PLoS One 7:e34212. doi:10.1371/journal.pone.0034212.
40. Mertens M, et al. 2011. Seroprevalence study in forestry workers of a non-endemic region in eastern Germany reveals infections by Tula and Dobrava-Belgrade hantaviruses. Med. Microbiol. Immunol. 200:263-268.
41. Mévélec MN, et al. 1998. Mapping of B epitopes in GRA4, a dense granule antigen of Toxoplasma gondii and protection studies using recombinant proteins administered by the oral route. Parasite Immunol. 20:183-195.
42. Mezzasoma L, et al. 2002. Antigen microarrays for serodiagnosis of infectious diseases. Clin. Chem. 48:121-130. (Pubitemid 34038131)
43. Montoya JG, Liesenfeld O. 2004. Toxoplasmosis. Lancet 363:1965-1976. (Pubitemid 38759657)
44. Nahtman T, et al. 2007. Validation of peptide epitope microarray experiments and extraction of quality data. J. Immunol. Methods 328:1-13. (Pubitemid 350007612)
45. Ngo Y, et al. 2009. Identification and testing of control peptides for antigen microarrays. J. Immunol. Methods 343:68-78.
46. Noya O, Patarroyo ME, Guzmán F, Alarcón de Noya B. 2003. Immunodiagnosis of parasitic diseases with synthetic peptides. Curr. Protein Pept. Sci. 4:299-308. (Pubitemid 36975112)
47. Pamelard F, et al. 2009. PASE: a web-based platform for peptide/protein microarray experiments. Methods Mol. Biol. 570:413-430.
48. Reineke U, Schutkowski M. 2009. Epitope mapping protocols. Preface. Methods Mol. Biol. 524:v-vi.
49. Reineke U. 2009. Antibody epitope mapping using de novo generated synthetic peptide libraries. Methods Mol. Biol. 524:203-211.
50. Roggen EL. 2006. Recent developments with B-cell epitope identification for predictive studies. J. Immunotoxicol. 3:137-149. (Pubitemid 44266963)
51. Saeij JP, Arrizabalaga G, Boothroyd JC. 2008. A cluster of four surface antigen genes specifically expressed in bradyzoites, SAG2CDXY, plays an important role in Toxoplasma gondii persistence. Infect. Immun. 76:2402-2410.
52. Saha S, Raghava GP. 2006. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins 65:40-48. (Pubitemid 44320614)
53. Shen G, Behera D, Bhalla M, Nadas A, Laal S. 2009. Peptide-based antibody detection for tuberculosis diagnosis. Clin. Vaccine Immunol. 16:49-54.
54. Sousa S, et al. 2009. Selection of polymorphic peptides from GRA6 and'GRA7 sequences of Toxoplasma gondii strains to be used in serotyping. Clin. Vaccine Immunol. 16:1158-1169.
55. Suzuki Y. 2002. Host resistance in the brain against Toxoplasma gondii. J. Infect. Dis. 185(Suppl. 1):S58-S65. (Pubitemid 34142830)
56. Tenter AM, Heckeroth AR, Weiss LM. 2000. Toxoplasma gondii: from animals to humans. Int. J. Parasitol. 30:1217-1258.
57. Travier L, et al. 2008. Functional domains of the Toxoplasma GRA2 protein in the formation of the membranous nanotubular network of the parasitophorous vacuole. Int. J. Parasitol. 38:757-773. (Pubitemid 351514750)
58. Vigil A, et al. 2010. Identification of the feline humoral immune response to Bartonella henselae infection by protein microarray. PLoS One 5:e11447. doi:10.1371/journal.pone.0011447.